Lingti Kong

409 citations
39 papers · 276 indexed · h-index 10
Topics
Antibiotics Pharmacokinetics and Efficacy (8 papers)Pharmacological Effects of Natural Compounds (6 papers)Antimicrobial Resistance in Staphylococcus (5 papers)
Partner nations
ChinaSpain

In The Last Decade

Lingti Kong

31 papers receiving 273 citations

Peers

Lingti Kong
Comparison fields: 5 of 65
  • Molecular Biology 119
  • Pharmacology 67
  • Pharmacology 48
  • Radiology, Nuclear Medicine and Imaging 35
  • Analytical Chemistry 35
Replace Jing Rong Wang with:
Jing Rong Wang Macao
Md. Al Amin Bangladesh
Muyan Kong China
Tianli Pei China
Hassan Khalid Sudan
Prabha Tiwari Japan
Serhiy Hnatyshyn United States
Kotha Anil Kumar India
Xianwen Ye China
Lingti Kong relative to Jing Rong Wang Macao Jing Rong Wang's profile →
Citations per field
00.5×1.5×2.3×
Jing Rong Wang · 1×
Citations per year

Countries citing papers authored by Lingti Kong

Since Specialization
Citations

This map shows the geographic impact of Lingti Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingti Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingti Kong more than expected).

Fields of papers citing papers by Lingti Kong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingti Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingti Kong. The network helps show where Lingti Kong may publish in the future.

Co-authorship network of co-authors of Lingti Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Lingti Kong. A scholar is included among the top collaborators of Lingti Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingti Kong. Lingti Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 1
4 0
5 0
6 5
7 0
8 3
9 7
10 0
11 2
12 2
13 4
14 9
15 35
16 3
17 21
18 36
19 34
20 17

About Lingti Kong

Lingti Kong is a scholar working on Pharmacology, Applied Microbiology and Biotechnology and Toxicology, having authored 39 papers that have together received 276 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (8 papers), Pharmacological Effects of Natural Compounds (6 papers) and Antimicrobial Resistance in Staphylococcus (5 papers). The work is most often cited by research in Pharmacology (67 citations), Complementary and alternative medicine (34 citations) and Applied Microbiology and Biotechnology (8 citations). Lingti Kong has collaborated with scholars based in China and Spain. Frequent co-authors include Qi Chang, Bing‐Xin Xiao, Yonghong Liao, Xinmin Liu, Yongmei Yang, Xiaoxi He, Rui‐Le Pan, Huimei Chen, Qian Wang and Xiaofei Wu. Their work appears in journals such as Scientific Reports, Frontiers in Immunology and Journal of Ethnopharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026